The haemostatic balance - Astrup revisited

Haemostasis

Volumn 29, Issue 1, 1999, Pages 58-71

  Gaffney, Patrick J ^a   Edgell, Tracey A ^a   Whitton, Colin M ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Fibrinolysis; Haemostatic balance; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 12; FIBRIN; KALLIKREIN; PROTEIN C; THROMBIN; THROMBOMODULIN; UROKINASE;

BLOOD CLOT LYSIS; BLOOD CLOTTING; CONFERENCE PAPER; FIBRIN FORMATION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; TISSUE INJURY;

EID: 0032829303     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000022461     Document Type: Conference Paper

References (69)

1. Astrup T: The haemostatic balance. Thromb Diath Haemorrh 1958;2: 347-356.
2. Astrup T: The biological significance of fibrinolysis. Lancet 1956;ii: 565-568.
3. Gaffney PJ, Templeman J, Mahmoud M, Joe F: Fibrin formation: The influence of plasminogen, thrombin and calcium, (abstract). 7th Int Congr Thromb, Valencia, 1982.
4. Edgell TA, Gaffney PJ: Modulation of fibrin thickness and its relevance to the composition and lysis of fibrin. Fibrinolysis 1999;10(suppl 4): 11.
5. Mouri H, Ohkubo T: Fibrinogen binds to heparin: The relationship of the binding of other adhesive proteins to heparin. Arch Biochem Biophys 1993;303:27-31.
6. Prentice CRM, Hampton KK, Grant PJ, Nelson SR, Nieuwenhuisen W, Gaffney PJ: The fibrinolytic response to ancrod therapy: Characterization of fibrinogen and fibrin degradation products. Br J Haematol 1993;83:276-281.
7. Collen D: On the regulation and control of figrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost 1980;43:77-89.
8. Collen D, Lijnen HR: Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991;78:3114-3124.
9. Thorsen S: Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-amino-carboxylic acids. Biochim Biophys Acta 1975;393:55-65.
10. Tran-Thang C, Kruithof EKO, Bachmann FJ: Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots. Clin Invest 1984;74:2009-2016.
11. Gaffney PJ: Fibrinolysis and the hypercoagulable state; in Seghatchian MJ, Samama MM, Hecker SP (eds): Hypercoagulable States. New York, CRC Press, 1996, p 117.
12. Ichinose A, Tamaki T, Aoki N: Factor XII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin. FEBS Lett 1983;153:369-371.
13. Takada A, Urano T, Takada Y: The regulation of the activation of the fibrinolysis system. Adv Exp Mcd Biol 1990;281:209-222.
14. Wiman B, Collen D: Molecular mechanisms of physiological fibrinolysis. Nature 1987;272:549.
15. 2-antiplasmin and plasminogen activator inhibitor-1 of clot lysis in vitro. Fibrinolysis 1990;4:169-175.
16. Marder VJ, Shulman NR: High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity. J Biol Chem 1969;244: 2120-2124.
17. Holt JC, Mahmoud M, Gaffney PJ: The ability of fibrinogen fragments to support ADP-induced platelet aggregation. Thromb Res 1979;16: 427-435.
18. Esmon NL, Owen WG, Esmon CT: Isolation of a membrane-bound co-factor for thrombin-catalyzed activation of protein C. J Biol Chem 1982;257:859-864.
19. Walker FJ, Fay PJ: Regulation of blood coagulation by the protein C system. FASEB J 1992;6:2561-2567.
20. Gaffney PJ, Longstaff C: An overview of fibrinolysis; in Bloom AL, Forbes CD, Tuddenham EGD, Thomas DP (eds): Thrombosis and Haemostasis. Edinburgh, Churchill Livingstone, 1994, pp 549-573.
21. Gaffney PJ, Willmott NJ, Longstaff C: Fibrinolysis. A delicate balance between enzymes and inhibitors; in Neri Sereri GG, Gensini GF, Abbate R, Prisco D (eds): Fibrinolysis. An Update. Florence, Scientific Press, 1992, pp 519-548.
22. Backmann F: Molecular aspects of plasminogen, plasminogen activators and plasmin; in Bloom AL, Forbes CD, Tuddenham EGD, Thomas DP (eds): Thrombosis and Haemostasis. Edinburgh, Churchill Livingstone, 1994, pp 575-613.
23. Thorsen S, Phillips M: Plasminogen activator inhibitors; in Castellino FT, Gaffney PJ, Samama MM, Takada A (eds): Fundamental and Clinical Fibrinolysis. Amsterdam, Elsevier, 1987, pp 83-98.
24. Gaffney PJ: Structure of fibrinogen and degradation products of fibrinogen and fibrin. Br Med Bull 1977; 33:245-251.
25. Francis CW, Marder VJ: A molecular model of plasmic degradation of crosslinked fibrin. Semin Thromb Haemost 1982;8:25-35.
26. Gaffney PJ: The occurence and clinical relevance of fibrin fragments in blood. Ann NY Acad Sci 1983;408: 407-423.
27. Gaffney PJ: D dimer. History of the discovery, characterisation and utility of this and other fibrin fragments. Fibrinolysis 1993;7(suppl 2): 2-8.
28. Graeff H, Hafter R: Detection and relevance of crosslinked fibrin derivatives in blood. Semin Thromb Haemost 1982;8:57-68.
29. Gaffney PJ: Distinction between fibrinogen and fibrin degradation products in plasma. Clin Chim Acta 1975;65:109-115.
30. Gaffney PJ, Edgell TA, Creighton-Kempsford LJ: Fibrin degradation products (FnDP) assays. Analysis of standardisation issues and target antigens in plasma. Br J Haematol 1995;90:187-194.
31. Laurent TC, Blombäck B: On the significance of the release of two different peptides from fibrinogen during clotting. Acta Chem Scand 1958; 12:1875-1877.
32. Kudryk BJ, Collen D, Woods KR, Blombäck B: Evidence of localization of polymerization sites in fibrinogen. J Biol Chem 1974;249: 3322-3325.
33. Hermans J, McDonagh J: Fibrin: Structure and interactions. Semin Thromb Haemost 1982;8:11-24.
34. Gron B, Bennick A, Nieuwenhuisen W, Brosstad F: Normal and fibrinaemic patient plasma contain high-molecular weight crosslinked fibrin-(ogen) derivatives with intact fibrinopeptide A. Thromb Res 1990;57: 259-270.
35. Eisenberg PR, Jaffe AS, Stump DC, Collen D, Bovill EG: Validity of enzyme-linked immunosorbent assays of crosslinked fibrin degradation products as a measure of clot lysis. Circulation 1990;82:1159-1168.
36. Eisenberg PR, Rylatt DB, Rusticali F, Ferrini D, Ottani F, Galvani M: The importance of antibody specificity in measuring cross-linked fibrin degradation products by ELISA. Blood Coagul Fibrinolysis 1997;8:105-113.
37. Griffin JH: Clinical studies of protein C. Semin Thromb Haemost 1984;10:162-166.
38. Dahlback B: Protein S and C4b-binding protein: Components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991;66:49-61.
39. Ohlin A-K, Stenflo J: Some structure-function relationships in protein C pathway: in Aznour J, España F (eds): Barcelona, Springer-Verlag Iberica, 1990, pp 11-24.
40. Walker FJ, Sexton PW, Esmon CT: The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochim Biophys Acta 1979;571:333-342.
41. Suzuki K, Nishioka J, Hashimoto S: Regulation of activated protein C by thrombin-modified protein S. J Biochem 1983;94:699-705.
42. Walker FJ: Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem 1980;255:5521-5524.
43. Zoltan RP, Seegers WH: Autoprothrombin II-A: Thrombin removal and mechanism of induction of fibrinolysis. Thromb Res 1973;3:23-33.
44. Stenflo J: A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterisation. J Biol Chem 1976;251: 355-363.
45. Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH: Mechanism of protein C-dependent clot lysis: Role of plasminogen activator inhibitor. Blood 1986;68: 1218-1223.
46. Bajzar L, Fredenburgh JC, Nesheim M: The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system. J Biol Chem 1990;265:16948-16954.
47. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270:14477-14484.
48. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L: Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997;78:386-391.
49. Esmon CT: Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 1993; 70:29-35.
50. Kojima Y, Urano T, Kojima K, Serizawa K, Takada Y, Takada A: The significant enhancement of fibrinolysis by calcium ion in a cell free system: The shortening of euglobulin clot lysis time by calcium ion. Thromb Haemost 1994;72:113-118.
51. Kluft C, Wijngaards G, Jie AFH: Intrinsic plasma fibrinolysis: Involvement or urokinase-related activity in the factor XII-independent plasminogen proactivator pathway. J Lab Clin Med 1984;103:408-419.
52. Miles LA, Griffin JH: The role of molecules immunologically related to urokinase in contact system-dependent fibrinolysis; in Castellino FJ, Gaffney PJ, Samama MM, Takada A (eds): Fundamental and Clinical Fibrinolysis. Amsterdam, Elsevier, 1987, pp 45-55.
53. Miles LA, Rothschild Z, Griffin JH: Dextran-sulphate dependent fibrinolysis in whole human plasma: Dependence on factor XII and prekallikrein. J Lab Clin Med 1983;101: 214-225.
54. Kluft C, Dooijeward G, Emeis JJ: Role of the contact system in fibrinolysis. Semin Thromb Haemost 1987;13:50-68.
55. Kluft C, Jie AFH: Interaction between the extrinsic and intrinsic systems of fibrinolysis; in Davidson JF, Cepelak V, Samama MM, Desmoyers PC (eds): Progress in Chemical Fibrinolysis and Thrombolysis. Edinburgh, Churchill Livingstone, 1979, pp 25-31.
56. Egberg N, Gallimore MJ, Green K, Jacobsson J, Vesterqvist D, Wiman B: Effects of plasma kallikrein and bradykinin infusions into pigs on plasma fibrinolytic variables and urinary excretion of thromboxane and prostacyclin metabolites. Fibrinolysis 1988;2:101-106.
57. Huisveld IA, Haspers H, Van Heeswijk GM, Bernink MJE, Erich WBM, Bouma BN: Contribution of contact activation factors to urokinase-related fibrinolytic activity in whole human plasma (abstract). Thromb Haemost 1985;54:102.
58. Hauert J, Bachmann F: Prourokinase activation in the euglobulin fractions (abstract). Thromb Haemost 1985;54:122.
59. Blasi F: Surface receptors for urokinase plasminogen activator. Fibrinolysis 1988;2:73-84.
60. Duffy MJ: Urokinase-type plasminogen activator and malignancy - Review. Fibrinolysis 1993;7:295-302.
61. Plow EF, Felez J, Miles LA: Cellular regulation of fibrinolysis. Thromb Haemost 1991;66:32-36.
62. Miles LA, Plow EF: Fibrinolysis and cell surfaces; in Castellino FJ, Gaffney PJ, Samama MM, Takada A (eds): Fundamental and Clinical Fibrinolysis. Amsterdam, Elsevier, 1987, pp 111-123.
63. Stephens RW, Pollanen J, Tapiovaara H, Leung KC, Sim PS, Salonen EM, Ronne E, Behrendt N, Dano K, Vaheri A: Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J Cell Biol 1989;108:1987-1995.
64. Miles LA, Plow EF: Plasminogen receptors: Ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 1988;2:61-71.
65. Hajjar KA, Hamel NM, Harpel PC, Nachmann NL: Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest 1987;870:1712-1719.
66. Stopelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK: Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985;82:4939-4943.
67. Gaffney PJ, Creighton-Kempsford LJ, Tymkewycz PM: Detection of fibrin and its fragments using monoclonal antibodies. Clinical implications; in Nagy I, Losanczy H, Vinazzer H (eds): Thrombosis and Haemorrhagic Disorders. Würzburg, Schmitt & Meyer, 1990. pp 121-134.
68. Gaffney PJ, Edgell TA: Fibrinolysis and the haemostatic balance: Harmonisation of some old and new concepts; in Takada T, Collen D, Gaffney PJ (eds): Recent Progress in Blood Coagulation and Fibrinolysis. Amsterdam, Elsevier, 1997, pp 127-141.
69. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister H-E: FXII (review). Blut 1990;61:258-266.